Forus Raises Over $160M in Funding to Build the Foundation

The company plans to use the funding to grow its operations and continue developing its technology.

Forus is an AI-powered network that connects doctors, pharmacies, payers, and biopharma companies to help patients access new treatments. Built into physician workflows, the platform automates the process between a treatment decision and a patient starting care, including insurance approvals, financial assistance, and prescription routing.

Forus supports all major drugs, payers and pharmacies in the US and is free for both doctors and patients. Simplifying complex processes helps doctors prescribe the right treatments with confidence and ensures patients can access them without delays.

Scientific progress in medicine is accelerating, but getting new treatments to patients remains slow and inefficient. On average, it takes 10–15 years, and about $2.6 billion to bring a drug to market. Even after FDA approval, many eligible patients still don’t receive treatment due to the complexity of the system. As a result, many promising drugs never reach the market, and those that do often reach only a small share of the patients who could benefit.

Forus is used by thousands of medical practices and health systems across all 50 U.S. states and is rapidly expanding into new specialties. Provider adoption has grown 10x year over year for the past two years, driven mainly by word of mouth. As a result, Forus now supports patients in nearly 80% of U.S. residential ZIP codes, including many with complex conditions who are receiving treatment for the first time.

Forus also provides visibility into how prescriptions move through the healthcare system, including where providers face delays, where patients drop off, and how treatments perform across populations. This insight helps life sciences companies improve research, launch drugs more effectively, and focus on harder-to-treat diseases. Five of the top 10 global biopharma companies already work with Forus.

Read More:gaiia Raises $40M in Series B Funding Led by JMI Equity

“Too often, patients miss out on the right treatment not because the therapy doesn't exist, but because the system to deliver it falls short,” said Kareem Zaki, Partner at Thrive Capital. “Forus is addressing this from first principles. By making therapies reliably accessible in practice, they can both improve outcomes today, and expand what’s possible in medicine over time.”

“Drug discovery is moving faster, but the system that turns it into real-world treatment isn’t,” said Sahir Jaggi, CEO and founder of Forus. “We are creating that missing layer. We're grateful to the clinicians across the country who already trust Forus to get their patients on treatment. There’s an opportunity to unlock an order of magnitude more treatment options for doctors and patients, and we are building a team whose ambition matches that goal.”

About Forus

Founded by Sahir Jaggi, Forus aims to speed up access to medicine for patients, doctors, and drug developers. The company is building a network that connects doctors, pharmacies, payers, and biopharma companies to accelerate the delivery of new treatments. Providers across all 50 U.S. states use its AI platform, which supports millions of patients every year.

Read More:Govineer Solutions Receives Strategic Growth Investment from TA